American Journal of Cancer Prevention
ISSN (Print): 2328-7314 ISSN (Online): 2328-7322 Website: Editor-in-chief: Nabil Abdel-Hamid
Open Access
Journal Browser
American Journal of Cancer Prevention. 2015, 3(3), 62-64
DOI: 10.12691/ajcp-3-3-4
Open AccessResearch Article

Malignant Phyllodes Tumor in Patient with Breast Cancer: A Case Report

Mehrdad Payandeh1, Hooshang Usefi2, Edris Sadeghi3, 4, and Masoud Sadeghi3, 4

1Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

2Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Kermanshah, Iran

3Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

4Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Pub. Date: May 31, 2015
(This article belongs to the Special Issue Advances in Breast Cancer)

Cite this paper:
Mehrdad Payandeh, Hooshang Usefi, Edris Sadeghi and Masoud Sadeghi. Malignant Phyllodes Tumor in Patient with Breast Cancer: A Case Report. American Journal of Cancer Prevention. 2015; 3(3):62-64. doi: 10.12691/ajcp-3-3-4


Background: Phyllodes tumors (PT) have an incidence of 1 per 100,000 women and account for only 0.5% of all breast neoplasms. Herein, we present a case of malignant PT characterized by stromal overgrowth of a high-grade spindle cell sarcoma with marked stromal pleomorphism. Which this disease is rare and the lack of standard care options for it. Case Report: A 36-year-old woman with a metastatic malignant PT presented to our clinic to discuss treatment options. Immunohistochemical analysis showed that the lesion was negative for estrogen and progesterone receptor and HER-2/neu, ki67 > 80% positive and vimentin positive. During a futher evaluation in computed tomography (CT) of the chest revealed multiple lung masses was seen. Pathology review of the mastectomy product at our institution confirmed the diagnosis of a malignant PT characterized by stromal overgrowth of a high-grade spindle cell sarcoma with marked stromal pleomorphism, a high mitotic rate, and areas of necrosis. She treated with chemotherapy regimen for soft tissues sarcoma consist of vincristine, cyclophosphamide, doxorubicine. After three courses of this regimen despite of decease in severity of dyspnea the breast mass lesion progressed and the therapy change to ifosfamide and etoposide combined with Nexavar (Sorafenib). At now, the patient is treating with this policy. Conclusions: We reported a patient with malignant PT should receive adjuvant chemotherapy to reduce the risk of recurrence. We suggest chemotherapy with ifosfamide and etoposide combined with Nexavar (Sorafenib) because it is a good policy for close treatment.

chemotherapy CT scan Phyllodes tumors Sorafenib

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Payandeh M, Sadeghi E, Sadeghi M, Eskandar AM. Different Presentation of Treatment in Carcinomatous Meningitis of Breast Cancer: Report of 3 Cases, American Journal of Cancer Prevention, 3 (1), 4-7, 2015.
[2]  Payandeh M, Khodarahmi R, Sadeghi M, Sadeghi E. Appearance of Acute Myelogenous Leukemia (AML) in a Patient with Breast Cancer after Adjuvant Chemotherapy: Case Report and Review of the Literature, Iran J Cancer Prev, 8 (2), 125-8, 2015.
[3]  Testori A, Meroni S, Errico V, Travaglini R, Voulaz E, Alloisio M. Huge malignant phyllodes breast tumor: a real entity in a new era of early breast cancer, World J Surg Oncol, 13 (1), 81, 2015.
[4]  Böcker W. Verh Dtsch Ges Pathol. [WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics], 86, 116-9, 2002.
[5]  Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, et al. Ann Surg Oncol. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast, Ann Surg Oncol, 14 (10): 2961-70, 2007.
[6]  Pacioles T, Seth R, Orellana C, John I, Panuganty V, Dhaliwal R. Cancer Manag Res. Malignant phyllodes tumor ofthe breast presenting with hypoglycemia: a case report and literature of review, Cancer Manag Res, 6, 467-73, 2014.
[7]  Souza JA, Marques EF, Guatelli C, Girão DS, Queroz T, Graziano L, et al. Malignant phyllodes tumor of the breast: case report, Rev Assoc Med Bras, 57 (5), 495-7, 2011.
[8]  Grabowski J, Salzstein SL, Sadler GR, Blair SL. Malignant phyllodes tumors: a review of 752 cases, Am Surg, 73 (10), 967-9, 2007.
[9]  NCCN Clinical Practice Guidelines in Oncology (2014 NCCN Guidelines), Breast Cancer, Version 1.2014, MS56. Available at:
[10]  Lenhard MS, Kahlert S, Himsl I, Ditsch N, Untch M, Bauerfeind I. Phyllodes tumour of the breast: clinical follow-up of 33 cases of this rare disease, Eur J Obstet Gynecol Reprod Biol, 138 (2), 217-21, 2008.
[11]  Akin M, Irkorucu O, Koksal H, Gonul II, Gultekin S, Kurukahvecioglu O, et al. Phyllodes tumor of the breast; a case series, Bratisl Lek Listy, 111 (5), 271-4, 2010.
[12]  Barth RJ Jr. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors, Breast Cancer Res Treat, 57 (3), 291-295, 1999.
[13]  Jara-Lazaro AR, Akhilesh M, Thike AA, Lui PC, Tse GM, Tan PH. Predictors of phyllodes tumours on core biopsy specimens of fibroepithelial neoplasms, Histopathology, 57 (2), 220-32, 2010.